Overview

Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to verify the superiority in efficacy (American College of Rheumatology 20%: ACR20) and investigate the pharmacokinetics and safety of CDP870 versus placebo without coadministration of MTX in active RA patients in whom MTX cannot be administrated.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Collaborator:
UCB Japan Co. Ltd.
Treatments:
Certolizumab Pegol